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LETTERS TO THE EDITOR 239our findings.6 Cyclophosphamide is well known to affect
TH1-mediated disease, but limited data exist for allergic diseases.
Interestingly, in our patient, several specific IgEs became unde-
tectable, yet presumably because of the extremely high pretreat-
ment level of milk-specific IgE, this did not abate, and even
after HiCy he continued to have food-related anaphylaxis to
milk. Although HiCy may reduce total and specific IgE levels
for at least 12 months, it may also reset IgE production. Indeed,
our patient developed new IgE sensitizations, albeit of unclear
clinical significance. Whether the persistence of clinical reactiv-
ity is due primarily to the residual amount of remaining milk-
specific IgE being produced by long-lived plasma cells,7 IgE
production and its persistence in the mucosa,8 effects on regula-
tory T cells9 or other factors less affected by HiCy cannot be
determined.
In conclusion, to our knowledge, this is the first case that
demonstrates the effect of HiCy on IgE levels in an individual
with food and respiratory allergies and demonstrates prolonged
and marked suppressive effects on some pre-existing IgE levels
along with the appearance of new IgE specificities. At least for
milk, his clinical reactivity remained unchanged based on
accidental exposures, clearly demonstrating a disconnect be-
tween IgE levels and clinical reactivity. How long these changes
will persist, and their long-term clinical relevance, remains to be
seen.
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Filaggrin gene mutation associations with pea-
nut allergy persist despite variations in peanut
allergy diagnostic criteria or asthma status
To the Editor:
Recently, our research team found a strong and significant
association between loss-of-function (LOF) mutations in filaggrin
(FLG), a gene that encodes a skin barrier protein, in European and
Canadian individuals with peanut allergy (PA).1 These mutations
result in a barrier defect and have been associated with atopic
dermatitis, asthma, and allergic rhinitis.2 This finding represents
the strongest genetic risk factor found to date for PA, a highly
heritable disease,3 with an estimated odds ratio (OR) between
1.9 (Canadian) and 5.3 (English, Dutch, and Irish combined).1
Because there is no uniformly accepted definition of PA short of
oral food challenge, it is worthwhile to examine whether the asso-
ciation between the FLG LOF mutations and PA varies with the
diagnostic criteria for PA. Furthermore, the frequent coexistence
of PAwith other atopic conditions may mean that the association
between PA and FLG LOF mutations is confounded. Although
we controlled for eczema in the European populations in our pre-
vious work, data on eczema were not available for the Canadian
control group; however, data on asthma were available. Asthma
is a potential confounder, as it has known relationships with both
PA4 and FLGmutations.5 By using statistical sensitivity analyses,
we examined the effect of PA diagnostic criteria and asthma on the
relationship between PA and FLG LOF mutations in a Canadian
PA case group. Because the PA case group was composed of
both English- and French-speaking individuals, we also investi-
gated whether the difference in OR between the Canadian and
European populations could be due to some common French-
Canadian mutations not yet identified in FLG.
Caucasian subjects from a well-described Canadian pediatric
PA case group were recruited (n 5 679), and DNAwas isolated
from salivary samples.1 One control group consisted of adult Cau-
casians recruited from the general population of Ontario, Canada;
DNAwas provided by the Ontario Population Genomics Platform
at The Centre for Applied Genomics (Toronto) (n 5 894).
A second control group of newborn babies from Quebec City
was sampled on the basis of French-Canadian surname (stored
blood; n 5 268).6 All samples were genotyped in Dundee, Scot-
land, for the 4 most common FLG LOF mutations found in
Caucasians (R501X, 2282del4, R2447X, and S3247X). rs and
accession numbers for mutations are available in the Online
Repository at www.jacionline.org (see Table E1).
‘‘Mutation carriers’’ were defined as those with heterozygous,
homozygous, or compound heterozygous mutations. Those indi-
viduals with none of the 4FLGmutations were classified as ‘‘non-
mutation carriers.’’ The association between mutation status and
PAwas comparedwith the Ontario control group, the Quebec con-
trol group, and the combined control group. To evaluate whether
the association between PA andmutation status changedwith case
TABLE I. Demographics: PA cases and controls
Characteristic PA cases Ontario controls Quebec controls
No. of subjects 674 894 268
Age (y)*
Mean 6 SD 9.3 6 4.0 65.5 6 10.2 9.7 6 0.5
Range 0-21 33-84 7-10
No. with
missing data
0 2 0
Sex
No. of males 416 281 157
Proportion of
males (CI)
0.617
(0.580-0.654)
0.315
(0.284-0.346)
0.586
(0.526-0.645)
*Age on January 1, 2009.
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the resulting OR trends with case definition were examined by us-
ing the combined control groups. The methodology and rationale
for these definitions are given in the Online Repository available
at www.jacionline.org (see Tables E2 and E3). To increase power,
case definitions were transformed into an ordered variable and the
association between PA and FLGmutations was examined by us-
ing regressionmodeling through increasingly stringent definitions
of PA to see whether the OR changed significantly.
We also examined the effect of asthma on FLGmutation status
and PA. Logistic regression using the Ontario control group was
conducted with PA status, age, sex, asthma, and interaction terms
for PA and age, PA and sex, and PA and asthma.Because theremay
be interaction betweenmutation status, asthma, and smoking,7 and
self-identified asthmatic patients may have significant misclassifi-
cation, analyses controlled for smoking history in the controls and
misclassification in the asthma variable in both controls and cases.
A constructed atopic asthma variable was used to control for the
effect of smoking with 4 assumptions: (1) Those individuals who
have atopic asthma in childhood are less likely to smoke as adults.
(2)Those adultswhohave asthma and have never smoked aremore
likely to have atopic asthma. (3) If a patient reports bronchial em-
physema, he or she does not have atopic asthma. (4) Asthma re-
ported in the case group is atopic. To examine the possibility of
error due to self-report of asthma, we completed a sensitivity anal-
ysis taking into account data from the PA registry that found that
6% had ‘‘forgotten’’ previously noted atopic history, while 12%
more reported atopic history on the current questionnaire than at
baseline registry recruitment. Random sampling and subsequent
logistic regression modeling was completed 100 times to see the
overall effect of error in asthma reporting on the relationship of
PA and FLG LOF mutations using these parameters.
Finally, a similar sensitivity analysis of PA status was
conducted, as PA status could be affected by the age disparity
between the Ontario control group and the cases, because it is
estimated that up to 20% of individuals with PA may have
resolution of their allergy.8 This sensitivity analysis also took into
account the 1% prevalence of PA in the general population.9
Of the 679 cases eligible to participate, 99.3% had good quality
DNA. Demographic information is presented in Table I. The 674
cases had approximately twice as many mutations as the controls
(20% vs 11%), and the OR for PA and FLG mutation status was
similar in the Ontario and Quebec control groups (Table II).
The genotype frequencies in cases and controls are shown in
the Online Repository available at www.jacionline.org (see
Table E4). Among the 13 case definitions, therewas no significantdifference in the OR for the relationship between PA and FLG
mutation status. Seven representative case definitions are shown
in Table III. Logistic regression of the ordered case definition
criteria variable produced similar results.
The self-reported prevalence of asthmawas 11% in the Ontario
controls, compared with 65% in the PA cases (see Table E5 in this
article’s Online Repository at www.jacionline.org). Univariate
analysis found PA status to be the strongest predictor of a muta-
tion, followed by asthma. Neither age nor gender had an apprecia-
ble relationship with the presence of FLGmutations on univariate
or multivariate analysis and were not included in the final model.
Multivariate logistic regression found no evidence for an effect of
asthma (OR, 1.12; 95% CI, 0.79-1.59) on the relationship
between PA (OR, 1.81; 95% CI, 1.29-2.55) and FLG LOF muta-
tions. The proportion of mutations was similar in those PA cases
with and without asthma. Peanut-allergic individuals with asthma
had at least 1 mutation in 19.8% of the cases (95% CI, 0.159-
0.236), while 18.7% (95% CI, 0.136-0.238) of the PA cases with-
out asthma had at least 1 mutation.
An additional analysis using a constructed atopic asthma
variable to control for the effect of smoking yielded similar
results. PA status remained significant (OR, 1.88; 95% CI, 1.27-
2.80), while history of atopic asthma was not (OR, 1.44; 95% CI,
0.59-3.53). Results were also unchanged after the sensitivity
analysis of the self-reported asthma variable, with only PA status
remaining significant in the multivariate analysis. The sensitivity
analysis on PA status similarly had little effect on the findings.
While 20% resolution in cases alone finds that both PA and
asthma status are nonsignificant, modeling 20% resolution of
cases with 1% prevalence in the general population finds that only
PA status remains significant in the multivariate model.
This study substantiates the relationship between PA and
FLG LOF mutations, and moreover this relationship appears
independent of diagnostic criteria of PA and history of asthma,
although residual confounding is always possible. All sets of di-
agnostic criteria used in this study were intended to define indi-
viduals with clinical allergy, although it is possible that some
individuals who were merely sensitized could have been
included in the less stringent definitions of PA. Despite this pos-
sibility, the association between the FLG LOF mutations and PA
does not appear to vary with the diagnostic criteria for PA.
Although the point estimates for the OR increase as the PA def-
inition becomes more stringent, the sample size decreases and
the CIs overlap; thus, the differences are not statistically
significant.
The similarity of the OR in the 2 control groups provides
indirect evidence that it is unlikely that there are common FLG
mutations not yet identified in French-Canadians, under the as-
sumption of similar prevalence of PA. If unidentified common
French-Canadian FLG variants exist, one would expect the ob-
served OR to be higher when the PA cases were compared with
the Quebec controls, due to a lower detection of mutations in the
control group. However, further evidence such as the sequencing
of FLG in French-Canadians would be of interest.
Limitations of this study include the inability to verify ethnicity
by using geneticmarkers of ethnicity, whichwere not available for
either the cases or controls. However, of the 47 identifiedFLGmu-
tations, those examined here are shared in many European popu-
lations2 (see Table E6 in this article’s Online Repository at www.
jacionline.org), including the expected ancestries of our case and
control groups, giving us confidence that population stratification
TABLE II. FLG genotypes and statistical tests of PA cases compared with control groups
PA cases Ontario controls Quebec controls Combined controls
No. of analyzed subjects* 663 889 267 1156
No. of FLG heterozygotes 112 94 29 123
No. of FLG homozygotes/compound heterozygotes 18 4 1 5
Total no. with 1 or 2 FLG mutations 130 98 30 128
Proportion with 1 or 2 FLG mutations 0.196 0.110 0.112 0.110
OR NA 1.97 1.93 1.96
95% CI NA 1.47-2.65 1.24-3.06 1.49-2.58
x2 test (P value) NA 22.33 (2.30 3 1026) 9.37 (2.21 3 1023) 25.22 (5.12 3 1027)
NA, Not applicable.
*Genotyping failures occurred in 11 PA cases, 5 of the Ontario controls, and 1 of the Quebec controls.
One FLG mutation detected.
Two of the same (FLG homozygote) or 2 different (compound heterozygote) FLG mutations detected.
TABLE III. PA case definition analysis (PA cases compared with the combined control group)
No. of
subjects OR 95% CI
Minimum criteria to be considered for inclusion:
a. Convincing history of PA* and (i) SPT >_3 mm or (ii) psIgE >_ 0.35 kU/L or
b. No history of peanut ingestion/uncertain history of allergy and (i) SPT >_3 mm and (ii) psIgE >_15 kU/L or
c. Any history suggestive of an IgE-mediated reaction not compatible with anaphylaxis and (i) SPT >_8 mm or
(ii) SPT >_4 mm if <2 y old or (iii) psIgE >_15 kU/L or
d. Positive OFC
674 1.96 1.49-2.58
psIgE >_15 kU/L or SPT >_8 mm, or positive OFC 526 1.97 1.47-2.65
psIgE >_57 kU/L or SPT >_8 mm, or positive OFC 486 2.07 1.53-2.78
psIgE >_57 kU/L or SPT >_15 mm, or positive OFC 267 2.07 1.42-2.96
psIgE >_15 kU/L, or SPT >_8 mm AND anaphylaxis, or positive OFC 266 2.09 1.44-3.00
psIgE >_57 kU/L, or SPT >_8 mm AND anaphylaxis, or positive OFC 253 2.21 1.52-3.18
psIgE >_57 kU/L, or SPT >_15 mm AND anaphylaxis, or positive OFC 122 2.28 1.38-3.69
OFC, Oral food challenge; psIgE, peanut-specific immunoglobulin E; SPT, skin prick test.
*A convincing history was defined as a minimum of 2 mild symptoms/signs or either 1 moderate or 1 severe symptom/sign occurring within 120 min after peanut contact or
ingestion. (1) Mild: pruritus, urticaria, flushing, and/or rhinoconjunctivitis. (2) Moderate: angioedema, throat tightness, change in voice, coughing, difficulty breathing (other than
wheeze), nausea and/or vomiting, and/or abdominal pain. (3) Severe: wheezing, stridor, cyanosis, and/or circulatory collapse.
The definition used in our previous work1 required a history of anaphylaxis or a history suggestive of type I hypersensitivity to peanut along with SPT >_8 mm and psIgE >_15 kU/L.
J ALLERGY CLIN IMMUNOL
VOLUME 132, NUMBER 1
LETTERS TO THE EDITOR 241is not the cause of the difference in mutation frequency in the
cases and controls. The rate of mutations in the control groups
is comparable to the number seen in other Caucasian general pop-
ulations (Table E6), which also leads us to believe that we have not
overestimated the association. This studywas also impeded by the
inability to confirm asthma status by diagnosticmeans and that the
only control group for which we had asthma and smoking history
was a group of adults. While genotype will not change with age,
the age difference could have affected ethnicity (eg, through dif-
ferent times of immigration) and PA status because of genera-
tional lifestyle, dietary, or environmental differences. Asthma
status could also be affected by this age difference, because of
smoking history, failure to remember a history of childhood
asthma, as well as the possibility that cases have not yet developed
asthma, although there is already a large proportion of PA cases
who report asthma. In an effort to address these issues, sensitivity
analyses of both PA and smoking status were undertaken, which
found no appreciable effects on the findings of this study.
The results of this study lend credence to the hypothesis that
sensitization in allergic disease in at least some patientsmay occur
through the skin.10 Household peanut consumption is a risk factor
for the development of PA11 andmay be a proxy for the amount of
cutaneous peanut exposure for a young child. Sensitization to pea-
nut proteins may be related to cross-sensitization to aeroallergens,
such as birch pollen proteins that share homology with peanutallergens.12 As filaggrin is not expressed beyond the inferior tur-
binates, perhaps exposure to these homologous antigens through
the skin or mucosa could result in cross-sensitization to peanut.
If true, therapies targeted toward the skin, to either improve barrier
function or decrease inflammation, may prevent allergic disease.
Continued research in barrier function, immunologic mediators,
and environmental interactions is needed to further knowledge
of the pathogenesis of atopic diseases.
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House dust mite models: Will they translate
clinically as a superior model of asthma?
To the Editor:
House dust mite (HDM) is a common allergen associated with
allergic asthma. Consequently, HDM extracts are being more
widely used to model the allergic airway phenotype. Unfortu-
nately, as pointed out by Birrell et al,1 there is a paucity of preclin-
ical data demonstrating that HDM elicits classic features of
allergic asthma, namely, the early and late asthmatic responses.
Currently, the primary end points assessed in these models
continue to be airway inflammation and airway hyperreactivity.
Neither measure is necessarily a direct indicator of allergen-specific
responses in the airways, as bothmay certainly be the result of innate
responses to components contained within the HDM extract. For
instance, eosinophil numbers and TH2 cytokine levels were in-
creased in lavage fluid following a single HDM challenge in sham-
sensitized rats, leaving some to question whether these systems are
truly modeling allergic airway disease.1,2 That said, several groups
have shown inmice thatHDMinduces an adaptive immune response
and airway hyperreactivity in a TH2-dependent fashion, which has
been linked to innate inflammatory changes occurring after mucosal
damage.3,4 However, no study has directly assessed whether HDM
can evoke antigen-induced bronchoconstriction responses in mice.
To specifically address this problem,we assessedwhetherHDM
could mimic the early asthmatic response (EAR) in mice. Asth-
matic patients with high levels of circulating HDM-specific IgE
develop acute bronchoconstriction after exposure to HDM. Mast
cells and basophils degranulate to release mediators (eg, histamine
and cysteinyl leukotrienes) that increase airflow resistance through
a reduction in the luminal diameter of the airways as a result of
airway smooth muscle contraction. In mice, allergen-induced
acute bronchoconstriction has been well characterized in the
classic ovalbumin model of allergic airway disease. Briefly, mice
systemically sensitized (alongwith an adjuvant) and then topically
or intravenously dosed with ovalbumin develop increased airways
resistance within minutes of exposure.5 Of note, there are species-
specific differences in how this response develops5,6; insteadof his-
tamine, 5-HT is the predominant preformed mediator released
from mast cells in mice and drives the EAR through a central ner-
vous system reflex instead of a direct effect on smooth muscle.6
That said, the primary mechanisms driving the EAR are similar
in mouse and man; the response in both species has been shown
to be IgE- and mast cell mediator–dependent.5-7
To assess whether HDM could induce a similar type I hyper-
sensitivity response in the airways, we intranasally administered
HDM extract (25mg) or saline tomale, BALB/c mice once daily, 5
days a week, for 1 to 3 weeks. Twenty-four hours after the last
administration, anesthetizedmicewere intravenously administered
HDM (25-250 mg) and respiratory system resistance (R) was mea-
sured by using the flexiVent system (SCIREQ, Montreal, Quebec,
Canada). Statistical significance for the experiments described be-
low was determined by using a 2-tailed t test of unpaired data sets,
with the exception of Fig 1,C, inwhich a 1-wayANOVAwas used.
HDM increased R within minutes of the intravenous injection,
which is characteristic of a mast cell–mediated response
METHODS
Although not predictive of reaction, the size of the skin prick wheal is
correlated to the probability of reaction on food challengeE1,E2 while the level
of peanut-specific immunoglobulin E is correlated to anaphylaxis on food
challenge.E3 After review of the literature, several case definitions were eval-
uated by using the criteria outlined in Table E2.
Because there is some evidence that the use of multiple test types may
improve the specificity of PA diagnosis,E13,E15,E16 various arrangements of
these criteria were evaluated by combining each peanut-specific immunoglob-
ulin E level and each skin prick test cutoff, or combining each peanut-specific
immunoglobulin E level or each skin prick test cutoff. These criteria were also
combined both with and without a clinical history of anaphylaxis as defined by
the consensus statement on anaphylaxis.E14 These parameters led to a contin-
uum of 13 separate case definitions for PA (Table E3).
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TABLE E1. rs and accession numbers of screened FLG mutations
Mutation Accession number rs number
R501X CM061002 rs61816761
2282del4 CD061417 rs41370446
R2447X CM071765 rs138726443
S3247X CM071767 rs150597413
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TABLE E2. Laboratory and clinical cutoffs used for case
definitions
Criterion Cutoff References
Peanut-specific IgE >_0.35 kU/L E4
>_15 kU/L E5-E7
>_26.5 kU/L E8
>_57 kU/L E9
Skin prick test >_3 mm E10
>_8 mm E5-E7,E11,E12
>_15 mm E9,E13
Oral food challenge Positive E5
Anaphylaxis 2 systems involved among
mucocutaneous, respiratory,
gastrointestinal, and cardiovascular
systems
E14
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TABLE E3. Thirteen case definitions of PA
Case definition
1. a. Convincing history of an allergic reaction to peanut and (i) SPT of >_3 mm to peanut or (ii) psIgE >_0.35 kU/L or
b. No history of peanut ingestion/uncertain history of PA and (i) SPT of >_3 mm and (ii) psIgE >_15 kU/L or
c. Any history suggestive of an IgE-mediated reaction not compatible with anaphylaxis as defined above and (i) SPT of >_8 mm or
(ii) SPT of >_4 mm if <2 y of ageE11,E17 or (iii) psIgE >_15 kU/L or
d. Positive OFC
2. psIgE >_15 kU/L or SPT >_8 mm or positive OFC
3. psIgE >_26 kU/L or SPT >_8 mm or positive OFC
4. psIgE >_57 kU/L or SPT >_8 mm or positive OFC
5. psIgE >_15 kU/L or SPT >_15 mm or positive OFC
6. psIgE >_26 kU/L or SPT >_15 mm or positive OFC
7. psIgE >_57 kU/L or SPT >_15 mm or positive OFC
8. psIgE >_15 kU/L or SPT >_8 mm and anaphylaxis, or positive OFC
9. psIgE >_26 kU/L or SPT >_8 mm and anaphylaxis, or positive OFC
10. psIgE >_57 kU/L or SPT >_8 mm and anaphylaxis, or positive OFC
11. psIgE >_15 kU/L or SPT >_15 mm and anaphylaxis, or positive OFC
12. psIgE >_26 kU/L or SPT >_8 mm and anaphylaxis, or positive OFC
13. psIgE >_57 kU/L or SPT >_8 mm and anaphylaxis, or positive OFC
OFC, Oral food challenge; psIgE, peanut-specific immunoglobulin E; SPT, skin prick test.
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TABLE E4. Number of subjects with FLG genotypes in PA cases
and controls
Genotype
n (%)
PA cases Ontario controls Quebec controls
NMC; NMC* 533 (80.4) 791 (88.9) 237 (88.8)
R501X; NMC 53 (8.0) 32 (3.6) 13 (4.9)
2282del4; NMC 39 (5.9) 44 (4.9) 10 (3.7)
R2447X; NMC 10 (1.5) 10 (1.1) 4 (1.5)
S3247X; NMC 10 (1.5) 8 (0.9) 2 (0.7)
R501X; R501X 3 (0.5) 0 0
2282del4; 2282del4 1 (0.2) 0 1 (0.4)
S3247X; S3247X 0 1 (0.1) 0
R501X; 2282del4 7 (1.1) 1 (0.1) 0
R501X; R2447X 3 (0.5) 0 0
R501X; S3247X 0 1 (0.1) 0
2282del4; R2447X 2 (0.3) 1 (0.1) 0
2282del4; S3247X 2 (0.3) 0 0
Genotype failure 11 5 1
Totals 674 894 268
*Nonmutation carrier; ie, none of the 4 FLG mutations found.
J ALLERGY CLIN IMMUNOL
JULY 2013
242.e5 LETTERS TO THE EDITOR
TABLE E5. Asthma, emphysema, and smoking history: PA cases
and controls
PA cases Ontario controls
No. of subjects 674 894
Asthma
No. with asthma 426 98
Proportion with asthma (CI) 0.645 (0.609-0.682) 0.110 (0.090-0.131)
No. with missing data 14 5
Bronchial emphysema
No. with bronchial emphysema NA 38
Proportion with bronchial
emphysema (CI)
NA 0.043 (0.029-0.056)
No. with missing data NA 2
Smoking
No. of smokers NA 496
Proportion of smokers (CI) NA 0.557 (0.524-0.589)
No. with missing data NA 3
NA, Not applicable.
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TABLE E6. FLG mutation frequencies in European populations
Population Mutation frequency (%) References
English 8-14 E18,E19
Irish 4-8 E20,E21
German 6 E22
Austrian 6 E23
Danish 7-8 E24,E25
French 4 E26,E27
Polish 5 E28
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